BPC June 24 update

uniQure QURE license deal diminishes hopes of buyout -13% AH; Offerings BSGM EVLO MGTA NK TBIO XERS

Price and Volume Movers

uniQure N.V. (NASDAQ:QURE) shares are trading down 13% after hours to $54.60, adding to a 7% fall during normal trading hours. The company announced a license agreement with CSL Behring for rights to etranacogene dezaparvovec, its gene therapy for patients with hemophilia B. uniQure will receive a $450m upfront payment and is eligible to receive up to $1.6b in milestone payments and tiered double-digit royalties in a range of up to a low-twenties percentage of net product sales arising from the collaboration. Shares fell on news as investors had pinned their hopes on a buyout of the company instead.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced its Phase 2/3 trial of troriluzole in the treatment of obsessive-compulsive disorder (OCD) did not meet its primary endpoint. Shares closed down 4% to $70.04.

Several companies announced public offerings after hours. Brief details below including after-hours price changes (all are after-hours except for BioSig which announced pre-market).

BioSig Technologies, Inc. (NASDAQ:BSGM): $7.58; -22%. Registered direct offering $17.5m (pre-market).

NantKwest, Inc. (NASDAQ:NK): 10.88; -10% AH. Common stock public offering.

Magenta Therapeutics, Inc. (NASDAQ:MGTA): Common stock offering $60m.

Translate Bio, Inc. (NASDAQ:TBIO): $25.90; -3% AH (closed +12% during normal hours). Common stock offering $125m.

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS): $4.52; -15% AH. Common stock offering $20m and $60m convertible senior notes.

Evelo Biosciences, Inc. (NASDAQ:EVLO): $3.70; -8% AH. Common stock offering $40m.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Vaxart, Inc. (VXRT): $3.19; +20%.

NovaBay Pharmaceuticals, Inc. (NBY): $1.23; +19%.

Vir Biotechnology, Inc. (VIR): $47.86; +19%.

Five Prime Therapeutics, Inc. (FPRX): $6.95; +18%.

Surface Oncology, Inc. (SURF): $6.01; +18%.

DECLINERS:

XTL Biopharmaceuticals Ltd. (XTLB): $1.30; -18%.

MannKind Corporation (MNKD): $1.86; -13%.

KalVista Pharmaceuticals, Inc. (KALV): $11.27; -13%.

Applied Therapeutics, Inc. (APLT): $38.81; -11%.

RAPT Therapeutics, Inc. (RAPT): $29.24; -11%.


Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ALPN – Alpine Immune Sciences Inc.
ALPN-202
Advanced Malignancies

Phase 1 Phase 1 initiation of dosing announced June 24, 2020.
$189.2 million

ALXN – Alexion Pharmaceuticals Inc.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3 Phase 3 trial met primary endpoint - June 24, 2020. Regulatory filing due 3Q 2021.
$24.8 billion

ARPO – Aerpio Pharmaceuticals Inc.
Razuprotafib (AKB-9778)
Open-angle glaucoma (OAG)

Phase 2 Phase 2 initiation announced June 24, 2020 with top-line data due 4Q 2020.
$51.1 million

BCLI – Brainstorm Cell Therapeutics Inc.
NurOwn
Prodromal to mild Alzheimer's disease

Phase 2 Phase 2 trial planned.
$359.2 million

BHVN – Biohaven Pharmaceutical Holding Company Ltd.
TRORILUZOLE
Obsessive compulsive disorder (OCD)

Phase 2/3 Phase 2/3 top-line data did not meet primary endpoint - June 24, 2020.
$4.2 billion

FULC – Fulcrum Therapeutics Inc.
Losmapimod
COVID-19

Phase 3 Phase 3 trial initiation announced June 24, 2020. Interim analysis due 4Q 2020 with top-line data due 1Q 2021.
$489.1 million

GRTS – Gritstone Oncology Inc.
GRANITE-001 (GO-004)
Solid tumors

Phase 1/2 Phase 1 data due July 13, 2020.
$245.2 million

IPHA – Innate Pharma S.A.
IPH4102 - TELLOMAK
Mycosis Fungoides and Sézary syndrome

Phase 2 Phase 2 partial clinical hold lifted - June 24, 2020. Mycosis fungoides data due in 2021. Sézary syndrome data due 2022.
$508.8 million

LCTX – Lineage Cell Therapeutics, Inc.
OpRegen
Dry age-related macular degeneration (AMD)

Phase 1/2 Phase 1/2 interim data presented June 27, 2020 at ISSCR Annual Meeting.
$118.4 million

MRK – Merck & Company Inc. (new)
Keytruda
Cutaneous squamous cell carcinoma (cSCC)

Approved FDA approval announced June 24, 2020.
$198.8 billion

NMTR – 9 Meters Biopharma Inc.
NM-002
Short bowel syndrome

Phase 1/2 Phase 1b/2a initiation announced June 24, 2020 with top-line data due 1H 2021.
$61.6 million

SNGX – Soligenix Inc.
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer

Phase 3 Phase 3 top-line data due 4Q 2020.
$52.1 million

XLRN – Acceleron Pharma Inc.
Sotatercept - PULSAR
Pulmonary arterial hypertension (PAH)

Phase 2 Phase 2 trial met primary endpoint - January 27, 2020. Data presented at American Thoracic Society (ATS) June 24, 2020 noted PVR reductions of 21-34% compared with 2% for placebo.
$5.5 billion

ZEAL – Zealand Pharma A/S
BI 456906
Obesity / diabetes

Phase 2 Phase 2 initiation of dosing announced June 24, 2020.
$1.4 billion